JOP20190003A1 - مشتق أوكسازين للاستخدام في الوقاية من مرض ألزهايمر في مرضى عُرضه للخطر - Google Patents

مشتق أوكسازين للاستخدام في الوقاية من مرض ألزهايمر في مرضى عُرضه للخطر

Info

Publication number
JOP20190003A1
JOP20190003A1 JOP/2019/0003A JOP20190003A JOP20190003A1 JO P20190003 A1 JOP20190003 A1 JO P20190003A1 JO P20190003 A JOP20190003 A JO P20190003A JO P20190003 A1 JOP20190003 A1 JO P20190003A1
Authority
JO
Jordan
Prior art keywords
alzheimer
disease
prevention
oxazine derivative
risk patients
Prior art date
Application number
JOP/2019/0003A
Other languages
English (en)
Inventor
Ulf Neumann
Cristina Lopez-Lopez
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20190003A1 publication Critical patent/JOP20190003A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بمثبط باس-1 مشتق أوكسازين وتركيبات صيدلانية تشمل مشتق الأوكسازين للاستخدام في الوقاية من مرض ألزهايمر في مريض عُرضه لتطور أعراض إكلينيكة لمرض ألزهايمر، وبشكل خاص، حيث يحمل المريض العُرضه لتطور أعراض إكلينيكة لمرض ألزهايمر نسخة أو اثنين من آليل ابو اي4.
JOP/2019/0003A 2016-07-19 2017-06-16 مشتق أوكسازين للاستخدام في الوقاية من مرض ألزهايمر في مرضى عُرضه للخطر JOP20190003A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16180233 2016-07-19
EP16193779 2016-10-13

Publications (1)

Publication Number Publication Date
JOP20190003A1 true JOP20190003A1 (ar) 2019-01-10

Family

ID=59626646

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0003A JOP20190003A1 (ar) 2016-07-19 2017-06-16 مشتق أوكسازين للاستخدام في الوقاية من مرض ألزهايمر في مرضى عُرضه للخطر

Country Status (18)

Country Link
US (2) US20180036315A1 (ar)
EP (1) EP3487504A1 (ar)
JP (1) JP2019524743A (ar)
KR (1) KR20190030691A (ar)
CN (1) CN109475562A (ar)
AU (1) AU2017298651A1 (ar)
BR (1) BR112019000902A2 (ar)
CA (1) CA3028629A1 (ar)
CL (1) CL2019000122A1 (ar)
IL (1) IL264040A (ar)
JO (1) JOP20190003A1 (ar)
MA (1) MA45719A (ar)
MX (1) MX2019000834A (ar)
PH (1) PH12018502703A1 (ar)
RU (1) RU2019101210A (ar)
SG (1) SG11201811022TA (ar)
TW (1) TW201805004A (ar)
WO (1) WO2018015868A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190081A1 (ar) 2016-10-13 2019-04-11 Novartis Ag مشتق أوكسازين للاستخدام في علاج أو الوقاية من اعتلال وعائي دماغي نشواني
CN113209087B (zh) * 2020-02-05 2023-11-07 歌礼药业（浙江）有限公司 一种抑制冠状病毒的药物组合物及其用途
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336966B (es) * 2011-01-13 2016-02-08 Novartis Ag Novedosos derivados y su uso en el tratamiento de transtornos neurologicos.
CA2851445A1 (en) * 2011-10-13 2013-04-18 Novartis Ag Novel oxazine derivatives and their use in the treatment of disease

Also Published As

Publication number Publication date
US20200345746A1 (en) 2020-11-05
IL264040A (en) 2019-01-31
JP2019524743A (ja) 2019-09-05
SG11201811022TA (en) 2019-02-27
CA3028629A1 (en) 2018-01-25
KR20190030691A (ko) 2019-03-22
TW201805004A (zh) 2018-02-16
CL2019000122A1 (es) 2019-04-12
EP3487504A1 (en) 2019-05-29
AU2017298651A1 (en) 2018-12-20
WO2018015868A1 (en) 2018-01-25
MX2019000834A (es) 2019-07-04
RU2019101210A (ru) 2020-08-19
MA45719A (fr) 2019-05-29
BR112019000902A2 (pt) 2019-04-30
CN109475562A (zh) 2019-03-15
US20180036315A1 (en) 2018-02-08
PH12018502703A1 (en) 2019-11-11

Similar Documents

Publication Publication Date Title
MX2019003363A (es) Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
PH12016502256A1 (en) Medical use
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
NZ735044A (en) Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
EA202090683A3 (ru) Способы и композиции для лечения рака
DK3119911T3 (da) Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
PH12018502703A1 (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
CY1121707T1 (el) Αναστολεας πρωτεϊνης μεταφορας εστερων χοληστερολης (cetp) και φαρμακευτικες συνθεσεις που περιλαμβανουν τον εν λογω αναστολεα για χρηση στη θεραπεια ή την προληψη καρδιαγγειακων νοσηματων
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
CY1118532T1 (el) Φαρμακευτικη συνθεση για χρηση στη θεραπευτικη αγωγη ή προληψη των ελλειψεων βιταμινων και μεταλλικων αλατων σε ασθενεις που εχουν υποβληθει σε επεμβαση γαστρικης παρακαμψης
MY186523A (en) Macrocyclic rip2 kinase inhibitors
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
CR20170426A (es) Inhibidores de bace 1
CY1119674T1 (el) Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad)
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas